Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $68 | $66 | $56 | $54 |
| - Cash | $1 | $2 | $6 | $4 |
| + Debt | $0 | $0 | $0 | $5 |
| Enterprise Value | $68 | $64 | $50 | $55 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$3 | $1 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.11 | -0.13 | 0.059 | -0.053 |
| % Growth | 15.4% | -318.9% | 211.9% | – |
| Operating Cash Flow | -$4 | -$3 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$3 | -$1 | -$1 |